Attenuation of epigenetic regulator SMARCA4 and ERK‐ETS signaling suppresses aging‐related dopaminergic degeneration

Ling Sun,Jie Zhang,Wenfeng Chen,Yun Chen,Xiaohui Zhang,Mingjuan Yang,Min Xiao,Fujun Ma,Yizhou Yao,Meina Ye,Zhenkun Zhang,Kai Chen,Fei Chen,Yujun Ren,Shiwei Ni,Xi Zhang,Zhangming Yan,Zhi‐Rong Sun,Hai‐Meng Zhou,Hongqin Yang,Shusen Xie,M. Emdadul Haque,Kun Huang,Yufeng Yang

DOI: https://doi.org/10.1111/acel.13210

IF: 11.005

2020-08-04

Aging Cell

Abstract:<p>How complex interactions of genetic, environmental factors and aging jointly contribute to dopaminergic degeneration in Parkinson's disease (PD) is largely unclear. Here, we applied frequent gene co‐expression analysis on human patient <i>substantia nigra</i>‐specific microarray datasets to identify potential novel disease‐related genes. In vivo<i> Drosophila </i> studies validated two of 32 candidate genes, a chromatin‐remodeling factor SMARCA4 and a biliverdin reductase BLVRA. Inhibition of SMARCA4 was able to prevent aging‐dependent dopaminergic degeneration not only caused by overexpression of BLVRA but also in four most common <i>Drosophila </i> PD models. Furthermore, down‐regulation of SMARCA4 specifically in the dopaminergic neurons prevented shortening of life span caused by α‐synuclein and LRRK2. Mechanistically, aberrant SMARCA4 and BLVRA converged on elevated ERK‐ETS activity, attenuation of which by either genetic or pharmacological manipulation effectively suppressed dopaminergic degeneration in <i>Drosophila </i> in vivo. Down‐regulation of SMARCA4 or drug inhibition of MEK/ERK also mitigated mitochondrial defects in <i>PINK1 </i> (a PD‐associated gene)‐deficient human cells. Our findings underscore the important role of epigenetic regulators and implicate a common signaling axis for therapeutic intervention in normal aging and a broad range of age‐related disorders including PD.</p>

cell biology,geriatrics & gerontology